Pharmasset
-
New Morningstar Analyst Report - Gilead Sciences
… 2012. The $11 billion acquisition of Pharmasset could give Gilead an edge in the growing ..... While the $11 billion acquisition of Pharmasset in January 2012 has drained most of ..... out on whether the $11 billion bet on Pharmasset was an excellent or poor use of capital …
-
Gilead's Hematology Pipeline: Transformative And Under-Appreciated
… GILD ) is garnering a huge amount of attention from investors owing to the hepatitis C virus (HCV) pipeline it got from the Pharmasset acquisition. As the market is occupied with the company's HCV programs, investors seem to ignore additional promising …
-
Finding An Oncology Player That Will Change The Rules Of The Game
… activity, for drugs with the potential to make a big difference. Gilead ( GILD ) shelled out a whopping $11 billion for Pharmasset last year, placing its bets on the success of GS-7977 (formerly known as PSI-7977), an experimental treatment for …
-
Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations
… 53.31 in early trade. Potential cure? Data has gradually emerged from the phase II Electron study since Gilead bought Pharmasset and GS-7977 late last year, for an eye watering $11bn. The multi -arm study has looked at a variety of patients and …
-
More Than 30% Upside For Gilead, Pfizer
… irrational level of risk discounting. Gilead ( GILD ), which bought out Pharmasset for $11 billion, now has a powerful hepatitis C drug in its pipeline. Pharmasset PSI-7977 is expected to begin Phase III trials in the second half of 2012 …
-
Wednesday, April 18th Bio-Pharma Mover Watch List
… INX-189 in a transaction that carried a whopping 163% premium, and Gilead Sciences ( GILD) , which struck a deal to buy Pharmasset in November 2011 for $11 billion. Gilead paid $137 per share for the company, which seized wide attention for its work …
-
This Week's Bio-Pharma Stock Movers: The Hep-C Market
… INX-189 in a transaction that carried a whopping 163% premium, and Gilead Sciences ( GILD ) , which struck a deal to buy Pharmasset in November 2011 for $11 billion. Gilead paid $137 per share for the company, which seized wide attention for its work …
-
Top Biotech Acquisition Candidates… hepatitis C. We've seen a couple of big deals close just recently. In January Gilead closed an $11 billion acquisition for Pharmasset . And then in February Bristol 's $2.5 billion deal for Inhibitex closed. I think there are a couple of other firms that …
close just recently. In January Gilead closed an $11 billion acquisition for Pharmasset . And then in February Bristol 's $2.5 billion deal for Inhibitex closed. I think there are a couple of other firms -
Joe DiMenna's Top Stock Picks
By Insider Monkey : Joe DiMenna is the Managing Director of Zweig DiMenna Partners. He co-founded the company, which is also one of the earliest alternative investment firms, with Martin Zweig in 1984. Business Week named DiMenna as "one of the best stock pickers no one has ever heard of" in 1999,
-
Will Medgenics Become The Next Hepatitis-C Take Over Candidate?
… driven by the need to pump up their product pipelines. Last November, Gilead Sciences ( GILD ) bought Princeton, NJ-based Pharmasset for $11 billion for the next generation of hepatitis-C treatments. Vertex Pharmaceuticals, working with Merck, is offering …